MaaT Pharma has published retrospective real-world data from its CHRONOS [...]

MaaT Pharma has reported its half year 2025 financial results, [...]

MaaT Pharma has randomized the first patient in the IMMUNOLIFE [...]

MaaT Pharma has reported a positive outcome from the second [...]

MaaT Pharma (EURONEXT: MAAT), a clinical-stage biotech focused on microbiome-based [...]

A new white paper from contract research organisation Novotech has [...]

MaaT Pharma has submitted a marketing authorisation application (MAA) to [...]